Paul Chamoulaud

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

Innovacom Gestion SAS (Innovacom) is a venture capital firm founded in 1988 and a subsidiary of Turenne Capital Partenaires. Innovacom is headquartered in Paris, France with additional offices in Stockholm and San Francisco.

Evolem SAS (Evolem) is a private equity and venture capital subsidiary of Bruno Rousset SAS founded in 1996 by Bruno Rousset. The firm is headquartered in France.

Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector.

Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.

Abénex Capital SAS is an Independent Private Equity firm founded in 1957 by Hervé Claquin. Abénex Capital is headquartered in Paris.

Naxicap Partners SA operates as a private equity firm. It invests in hospitals, pharmaceuticals, business services, information technology, textile, and consumer goods sectors. The company was founded in 1995 and is headquartered in Paris, France.

Paluel-Marmont Capital SA (PMC) is the wholly-owned private equity subsidiary of Compagnie Lebon (XP: LBON) in France. Formerly known as Lebon Développement, the firm was established in 1991. Located in Paris, PMC invests their own equity in leveraged buy-outs in small- and mid-size businesses, sharing their professional expertise and business network with investee company management.

XAnge Private Equity SA (XAnge Private Equity) is a private equity portfolio management firm which was created in 2003 by La Poste and ABN AMRO and is headquartered in France.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

La Redoute SAS operates as an online platform for electronic shopping. It offers clothing and accessories for men, women, and children. The firm also sells products for health, gardens, homes, and hobbies. Its services include delivery, after-sales, item exchange, and home installation. The company was founded by Joseph Pollet in 1835 and is headquartered in Roubaix, France.

A Plus Finance SA (A Plus Finance) is a private equity firm. The firm is founded in 1998 by Niels Court Payen andFrédéric Bayol. The firm headquartered in Paris, France.

Siparex XAnge Venture SAS is an Independent Venture Capital firm founded in 1977 by Benjamin Teszner. Siparex XAnge Venture SAS is headquartered in Paris.

M Capital Partners SASU is an Independent Private Equity firm founded in 2001 by Rudy Secco. M Capital Partners SASU is headquartered in Toulouse.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

MW Gestion SA is an independent financial asset management firm headquartered in Paris, France. The firm was founded in 1992 and offers UCITS funds and discretionary mandates, specialized in share and bond investments to individuals and institutional clients.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Germitec SA engages in the research, design, and marketing of medical hygiene systems. It develops Antigermix, which is used in disinfecting heat-sensitive medical instruments. The company was founded in 2005 and is headquartered in Ivry-sur-Seine, France.

Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.

Extens SAS (Extens) is an independent venture capital firm headquartered in Paris, France. The firm was founded by Arnaud Houette and Quentin Jacomet in 2013.

Essling Capital SAS (Essling Capital) is an independent private equity firm founded in 2016 by Frank-Noël Vandenberghe. The firm is headquartered in Paris, France.

Geneo Capital Entrepreneur SA is an Independent Private Equity/Venture Capital firm founded in 2018 by Fanny Letier. Geneo Capital Entrepreneur SA is headquartered in Neuilly-sur-Seine.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.